Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

<p>Abstract</p> <p>Background</p> <p>Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate and disability progression, and improves health-related quality of life (HRQoL), in patients with relapsing-remitting multiple scleros...

詳細記述

保存先:
書誌詳細
主要な著者: Stephenson Judith J, Kern David M, Agarwal Sonalee S, Zeidman Ruth, Rajagopalan Krithika, Kamat Siddhesh A, Foley John
フォーマット: Artigo
言語:Inglês
出版事項: BMC 2012-12-01
シリーズ:Health and Quality of Life Outcomes
主題:
Cognitive function
Health-related quality of life
Multiple sclerosis
Natalizumab
Patient-reported outcomes
オンライン･アクセス:http://www.hqlo.com/content/10/1/155
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料